EUVIMEDEUVIMED entdecken
Crossref

Liver cancer cells as the model for developing liver-targeted RNAi therapeutics

Beibei Hou, Linhui Qin, Linfeng Huang

Biochemical and Biophysical Research Communications · 2023

DOI: 10.1016/j.bbrc.2023.01.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2023. Verfasst von Beibei Hou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Wang-Cai Biochemistry Lab, Division of Natural and Applied Sciences, Duke Kunshan University, Kunshan, Jiangsu, China. Hauptthemen laut MEDLINE: Proprotein Convertase 9, Liver Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Duke Kunshan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RNAi is a sequence-specific gene regulation mechanism that involves small interfering RNAs (siRNAs). RNAi therapeutic has become a new class of precision medicine and has shown great potential in treating liver-associated diseases, especially metabolic diseases. To facilitate the development of liver-targeted RNAi therapeutics in cell model, we surveyed a panel of liver cancer cell lines for the expression of genes implicated in RNAi therapeutics including the asialoglycoprotein receptor (ASGR) and metabolic disease associated genes PCSK9, ANGPTL3, CIDEB, and LDLR. A high-content screen assay based on lipid droplet staining confirmed the involvement of PCSK9, ANGPTL3, and CIDEB in lipid metabolism in selected liver cancer cell lines. Several liver cancer cell lines have high levels of ASGR1 expression, which is required for liver-specific uptake of GalNAc-conjugated siRNA, a clinically approved siRNA delivery platform. Using an EGFP reporter system, we demonstrated Hep G2 can be used to evaluate gene knockdown efficiency of GalNAc-siRNA. Our findings pave the way for using liver cancer cells as a convenient model system for the identification and testing of siRNA drug candidate genes and for studying ASGR-mediated GalNAc-siRNA delivery in liver.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proprotein Convertase 9Liver NeoplasmsHumansRNAi TherapeuticsRNA InterferenceRNA, Small InterferingCell LineRNA, Double-StrandedAngiopoietin-Like Protein 3Asialoglycoprotein Receptor

Stichwörter der Autor:innen

ANGPTL3ASGRCIDEBGalNAcHepatocellular carcinomaPCSK9RNAisiRNA

Substanzen

PCSK9 protein, humanProprotein Convertase 9RNA, Small InterferingRNA, Double-StrandedANGPTL3 protein, humanAngiopoietin-Like Protein 3ASGR1 protein, humanAsialoglycoprotein Receptor

Autor:innen und Institutionen

  • Wang-Cai Biochemistry Lab, Division of Natural and Applied Sciences, Duke Kunshan University, Kunshan, Jiangsu, China.
  • Wang-Cai Biochemistry Lab, Division of Natural and Applied Sciences, Duke Kunshan University, Kunshan, Jiangsu, China; Global Health Research Center, Duke Kunshan University, Kunshan, Jiangsu, China. Electronic address:…

Förderung

  • Duke Kunshan University

Zitieren

APA

Hou, B., Qin, L., & Huang, L. (2023). Liver cancer cells as the model for developing liver-targeted RNAi therapeutics. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2023.01.007

Vancouver

Hou B, Qin L, Huang L. Liver cancer cells as the model for developing liver-targeted RNAi therapeutics. Biochemical and Biophysical Research Communications. 2023. doi:10.1016/j.bbrc.2023.01.007

BibTeX
@article{Hou2023,
  author = {Hou, Beibei and Qin, Linhui and Huang, Linfeng},
  title = {Liver cancer cells as the model for developing liver-targeted RNAi therapeutics},
  journal = {Biochemical and Biophysical Research Communications},
  year = {2023},
  doi = {10.1016/j.bbrc.2023.01.007}
}
Kostenlos starten →